The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms
about
Targeting the Pim kinases in multiple myelomaTargeting Pim kinases for cancer treatment: opportunities and challengesPim-1 kinase as cancer drug target: An updatePim-1 acts as an oncogene in human salivary gland adenoid cystic carcinomaA 20(S)-protopanoxadiol derivative overcomes multi-drug resistance by antagonizing ATP-binding cassette subfamily B member 1 transporter function.Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1PIM-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic value.PIM kinases: an overview in tumors and recent advances in pancreatic cancer.Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivoOvercoming ABCG2-mediated drug resistance with imidazo-[1,2-b]-pyridazine-based Pim1 kinase inhibitors.Pim kinase isoforms: devils defending cancer cells from therapeutic and immune attacks.ABCG2/BCRP: Specific and Nonspecific Modulators.PIM-1 mRNA expression is a potential prognostic biomarker in acute myeloid leukemia.Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia.Tyrphostin RG14620 selectively reverses ABCG2-mediated multidrug resistance in cancer cell lines.The positive inotropic agent DPI-201106 selectively reverses ABCB1-mediated multidrug resistance in cancer cell lines
P2860
Q26799499-2722583E-5E67-4A07-872F-14D9366F0108Q28255361-0279AF21-66A3-46BC-B31C-77E4AD823EFFQ28273475-6CAA0799-BB6C-4BD3-B22E-C73DCA70DE0CQ35005230-2060B572-7740-4983-80B7-8A8932012C3DQ36962615-093F380D-1386-4727-9021-4B6C0056A8ABQ37218015-75BCA27B-00FD-49A9-B0E3-B7B5A960AE34Q37233255-BE2CCF2F-9E1B-4400-9BF4-14B96CC6CC6BQ38209606-E4473D09-E2F0-4D88-81F9-5010432D85A6Q38710502-D2294EE1-C3A3-40C0-89B2-582780671279Q38836775-A094C176-F0FE-4A4E-96DE-DD30062959B8Q38960311-F27ACA20-79AE-4AA1-918B-841284F0B1CDQ39049159-33B808ED-DA74-44BC-9FDA-EDF3FF0127DEQ40066265-26423742-4C59-4EEF-9386-FF2AC50ECE80Q42380771-561B31DD-3EB4-4D17-9DF1-3DF92E579209Q47821418-73B9E68A-C519-47D3-9F19-196F89878CA9Q57283047-21A9BCBB-EC44-4964-864B-8C873574B154
P2860
The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 December 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The Pim kinase inhibitor SGI-1 ...... nt and -independent mechanisms
@en
The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein
@nl
type
label
The Pim kinase inhibitor SGI-1 ...... nt and -independent mechanisms
@en
The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein
@nl
prefLabel
The Pim kinase inhibitor SGI-1 ...... nt and -independent mechanisms
@en
The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein
@nl
P2093
P2860
P1476
The Pim kinase inhibitor SGI-1 ...... nt and -independent mechanisms
@en
P2093
Jasjeet Bhullar
Karthika Natarajan
Maria R Baer
Mehmet Burcu
Suneet Shukla
Suresh V Ambudkar
Zhe-Sheng Chen
P2860
P304
P356
10.1016/J.BCP.2012.12.006
P407
P577
2012-12-19T00:00:00Z